Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Stock Performance

Shares of Minerva Neurosciences stock opened at $2.18 on Tuesday. The stock has a market cap of $15.24 million, a price-to-earnings ratio of -4.95 and a beta of 0.11. The stock has a 50 day moving average price of $2.22 and a 200-day moving average price of $2.58. Minerva Neurosciences has a one year low of $2.06 and a one year high of $13.49.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.